Charles River Laboratories International, INC 8-K filings

Charles River Laboratories reported Q2 2026 results, exceeding prior outlook and increasing full-year guidance for revenue and non-GAAP EPS due to improving demand in DSA and Manufacturing segments.

Charles River Laboratories International, Inc. shareholders approved the 2026 Long-Term Incentive Plan at the annual meeting, alongside the election of directors and ratification of auditors.

Charles River Laboratories reported Q1 2026 results with revenue increasing 1.2% year-over-year to $995.8 million, while GAAP loss per share was $(0.30) and non-GAAP EPS was $2.06, down from the prior year.

Charles River Laboratories announced definitive agreements to divest its CDMO, Cell Solutions, and certain European Discovery Services businesses, updating its 2026 financial guidance.

Charles River Laboratories International, Inc. provided an optimistic 2026 outlook, citing improving demand trends in its Discovery and Safety Assessment business and announcing two strategic acquisitions.

Charles River Laboratories International, Inc. announced a leadership transition plan, with Birgit Girshick appointed as the new CEO, succeeding James C. Foster, effective May 5, 2026.

Charles River Laboratories International, Inc. reports continued improvement in Discovery and Safety Assessment net book-to-bill trends since Q3 2025, despite potential holiday seasonality.

Charles River Laboratories announced the SEC's Division of Enforcement concluded its investigation into primate sourcing without recommending enforcement action.

Charles River Laboratories International, Inc. announced third-quarter 2025 financial results, reporting $1.00 billion in revenue and updating its full-year 2025 guidance.

Charles River Laboratories International, Inc. filed an amendment to disclose the compensation package for its interim Chief Financial Officer, Michael G. Knell.

Charles River Laboratories announced the resignation of its CFO, Flavia H. Pease, effective September 29, 2025, with Michael G. Knell appointed as interim CFO.

Charles River Laboratories reported a 0.6% increase in second-quarter revenue to $1.03 billion, with non-GAAP earnings per share rising 11.4% to $3.12, leading to an upward revision of its 2025 financial guidance.

Charles River Laboratories International, Inc. announced the extension of CEO James C. Foster's employment agreement until February 2027 and the results of its Annual Meeting, including the election of seven directors, appointment of four new directors, approval of executive compensation and auditors, and rejection of a PETA shareholder proposal.

Charles River Laboratories has reached a cooperation agreement with Elliott Investment Management, appointed four new directors to its board, and initiated a strategic review to boost long-term shareholder value.

Charles River Laboratories reported a revenue decrease in Q1 2025 but increased its full-year 2025 financial guidance due to improved DSA bookings.

Charles River Laboratories' CEO and COO demonstrate confidence in the company's future by purchasing shares in the open market, while also terminating their existing Rule 10b5-1 trading plans.

Charles River Laboratories reports a slight revenue decrease in Q4 2024 and provides 2025 guidance, including planned stock repurchases of approximately $350 million.

Charles River Laboratories projects a revenue decline and margin pressure for 2025, citing biopharma spending constraints and CDMO business challenges.

Charles River Laboratories has amended and restated its credit agreement, reducing its revolving commitments to $2 billion while extending the maturity date to December 13, 2029.

Charles River Laboratories announced a slight revenue decrease in Q3 2024, alongside updated financial guidance for the year.

Charles River Laboratories announced a decrease in second-quarter revenue and revised its 2024 guidance due to weaker demand, particularly in its Discovery and Safety Assessment segment.

Charles River Laboratories held its annual shareholder meeting on May 8, 2024, electing eleven directors, approving executive compensation, and ratifying the appointment of PricewaterhouseCoopers as independent auditors.

Charles River Laboratories announced a slight revenue decrease in Q1 2024, with varied performance across its segments, while reaffirming its full-year financial outlook.

Charles River Laboratories announced a decrease in fourth-quarter revenue and provided 2024 guidance, reflecting a cautious biopharmaceutical demand environment.

Charles River Laboratories has increased its board size and appointed Reshema Kemps-Polanco as a new director, effective January 22, 2024.

Charles River Laboratories announced the retirement of its Chief Commercial Officer, William D. Barbo, at the end of 2024 and the appointment of Kristen Eisenhauer as his successor.